European Journal of Surgical Oncology
Volume 34, Issue 11 , Pages 1208-1216 , November 2008

An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer

  • T.S. Liu

      Affiliations

    • Department of Medical Oncology, Zhong Shan Hospital, Fu Dan University, 180 Feng Lin Road, Shanghai, 200032, China
    • ,
  • Y. Wang

      Affiliations

    • Department of Medical Oncology, Zhong Shan Hospital, Fu Dan University, 180 Feng Lin Road, Shanghai, 200032, China
    • ,
  • S.Y. Chen

      Affiliations

    • Department of Gastroenterology, Zhong Shan Hospital, Fu Dan University, 180 Feng Lin Road, Shanghai, 200032, China
    • ,
  • Y.H. Sun

      Affiliations

    • Department of General Surgery, Zhong Shan Hospital, Fu Dan University, 180 Feng Lin Road, Shanghai, 200032, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 21 64041990; fax: +86 21 52303355.

,Accepted 5 February 2008.

References 

  1. Katherine DC, Alfred IN. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–363
  2. Parkin D, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49(1):33–64
  3. Hermans J, Bonenkamp JJ, Boon M, et al. Adjuvant therapy after curative resection for gastric cancer: a meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441–1447
  4. Earle C, Maroun J. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer. 1999;35(7):1059–1064
  5. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. Ann Oncol. 2000;11(7):837–843
  6. Ochiai T, Sato H, Hayashi R, Asano T, Sato H, Yamamura Y. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. Three- to six-year follow-up of a randomized clinical trial. Cancer Immunol Immunother. 1983;14(3):167–171
  7. Jakesz R, Dittrich C, Funovics J, et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res. 1988;110(1988):44–51
  8. Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1989;1(Mar):571–574
  9. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet. 1994;343(8909):1309–1312
  10. Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88(1):21–27
  11. Higgins GA, Amadeo JH, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A veterans administration surgical oncology group report. Cancer. 1983;52(6):1105–1112
  12. Neri B, Leonardis V, Romano S, et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multi-centre randomised study. Br J Cancer. 1996;73(4):549–552
  13. Alderson P, Green S, Higgins JPT, editors. Cochrane reviewers' handbook 4.2.3, section 9.2 [updated May 2005]. Available at http://www.cochrane.dk/cochrane//handbook/hbook.htm.
  14. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820–826
  15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  17. Alcobendas F, Milla A, Estape J, Curto J, Pera C. Mitomycin-C as an adjuvant in resected gastric cancer. Ann Surg. 1983;198(1):13–17
  18. Sakuramoto S, Sasakoa M, Yamaguchi T, et al. Adjuvant chemotherapy using S-1 for curatively resected gastric cancer: the nationwide clinical trial. N Engl J Med. 2007;357(18):1810–1820
  19. Bouché O, Ychou M, Burtin P, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2006;16(9):1488–1497
  20. Estape J, Grau JJ, Lcobendas F, et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg. 1991;213(3):219–221
  21. Blake JR, Hardcastle JD, Wilson RG. Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. Clin Oncol. 1981;7(1):13–27
  22. Petrioli R, Sabatino M, Roviello F, et al. Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancer. Hepato-Gastroenterol. 2005;52(65):1626–1630
  23. Maehara Y, Emi Y, Sugimachi K, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol. 1990;45(3):169–172
  24. Bonfanti G, Gennari L, Bozzette F, et al. Adjuvant treatments following curative resection for gastric cancer. The Italian Gastrointestinal Tumor Study Group. Br J Surg. 1988;75:1100–1104
  25. Bajetta E, Aitini E, Bozzetti F, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13(2):299–307
  26. Chou FF, Sheen-Chen SM, Liu PP, Chen FC. Adjuvant chemotherapy for resectable gastric cancer: a preliminary report. J Surg Oncol. 1994;57(4):239–242
  27. Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999;17(12):3810–3815
  28. Coombes RC, Schein PS, Chilvers CED, et al. A randomised trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J Clin Oncol. 1990;8(8):1362–1369
  29. Engstrom PF, Lavin PT, Douglass HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275). Cancer. 1985;55(9):1868–1873
  30. Grau JJ, Estape J, Alcobendas F, et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer. 1993;29A(3):340–342
  31. Huguier M, Destroyes JP, Baschet C, Henand F, Bernard PF. Gastric carcinoma treated by chemotherapy after resection. Am J Surg. 1980;139(2):197–199
  32. Krook JE, O'Connell MJ, Wieand HS, et al. A prospective randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer. 1991;67(10):2454–2458
  33. Lise M, Nitti D, Marchet A, et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995;13(11):2757–2763
  34. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354(24):273–277
  35. Tsavaris N, Tentas K, Kosmidis P, et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy. 1996;42(3):220–226
  36. Douglass HO, Stablein DM, Bruckner HM, et al. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group. Cancer. 1982;49:1116–1122
  37. Macdonald JS, Fleming TR, Peterson RF, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: a Southwest Oncology Group study. Ann Surg Oncol. 1995;2(6):488–494
  38. Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21(12):2282–2287
  39. Neri B, Cini G, Andreoli G, et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. Br J Cancer. 2001;84(7):878–880
  40. Chipponi J, Huguier M, Pezet D, et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg. 2004;187(3):440–445
  41. Bresciani C, Waitzberg DL, Matsuda M, Gama-Rodrigues J, Strassmann V, Pinotti HW. Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. Rev Hosp Clin Fac Med Sao Paulo. 2001;55(4):129–136
  42. Uslu A, Karaca C, Nart A, et al. Adjuvant chemotherapy in a unique population of patients with gastric cancer undergoing surgery. Hepato-Gastroenterol. 2004;51(58):1245–1248
  43. Nakajima T, Fukami A, Ohashi I, Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm. 1978;16(5):209–216
  44. Schlag P, Schreml W, Gaus W, et al. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: three-year results. Recent Results Cancer Res. 1982;80(1982):277–283
  45. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol. 1984;2(12):1366–1371
  46. Hartgrink HH, Van de Volde CJH, Bonenkamp JJ, et al. Extended lymph-node dissection for gastric cancer: who may benefit? Final results of randomized Dutch Gastric Cancer Group trial. J Clin Oncol. 2004;22(11):2069–2077
  47. Kim JP. Immunochemosurgery as a new approach to reasonable treatment of advanced cancer. Ann Acad Med Singapore. 1988;17:48–54
  48. Yamamura Y, Nishimura M, Sakamoto J, et al. A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer. Gan To Tagaku Ryoho. 1986;13:2134–2140
  49. Schiessel R, Funovies J, Schick B, et al. Adjuvant intraperitoneal cisplatin in patients with operated gastric carcinoma: results of a randomized trial. Acta Med Aust. 1989;16:68–69

PII: S0748-7983(08)00068-1

doi: 10.1016/j.ejso.2008.02.002

European Journal of Surgical Oncology
Volume 34, Issue 11 , Pages 1208-1216 , November 2008

Article Tools

* Image Usage & Resolution